Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.

ABSTRACT:

Background

Given the complex nature of symptom presentation and medication regimens, psychiatric clinics may benefit from additional tools to personalize treatments. Utilizing pharmacogenetic information may be helpful in assessing unique responses to therapy. We report herein a case of wearing-off phenomena during treatment with aripiprazole long-acting injectable (LAI) and a proof of concept strategy of how pharmacogenetic information may be used to assess possible genetic factors and also hypothesize potential mechanisms for further study.

Case presentation

A 51-year-old African American male with schizoaffective disorder was referred to a psychiatric clinic for medication management. After unsuccessful trials of multiple antipsychotics, oral aripiprazole was initiated (u

SUBMITTER: Eum S 

PROVIDER: S-EPMC5496345 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature